Can a Drug for Overactive Bladder Prevent Heart Failure? : v

Repurposing mirabegron, a drug used to treat overactive bladder disease, did not significantly change left ventricular mass index or diastolic function in pre–heart failure structural heart disease.

Related Keywords

Brussels , Bruxelles Capitale , Belgium , United Kingdom , Wallonia , Waals Gewest , Jean Luc Balligand , European Commission , Amgen , Astrazeneca Foundation , Novartis , European Commission Horizon , Framework Programme , Wallonia Health , Institut De Recherche Expe , Catholique De Louvain , Biotech Cluster , Heart Failure , Heart , Cardiovascular Imaging , Ardiac Imaging , V Imaging , Overactive Bladder Oab , Ab Overactive Bladder , Hypertension , Cardiac Mri , Cardiac Magnetic Resonance Imaging , Ri Of The Heart , Agnetic Resonance Imaging Of The Heart , Atrial Fibrillation , F Atrial Fibrillation , Cardiomyopathy , Bladder , Europe , European , Tissue Doppler Imaging , Doppler Imaging , Oppler , Grant , Healthcare And M ,